



## Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma


### SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: Circulating LIF in serum from treatment-naïve oesophageal adenocarcinoma patients, divided according to pathological parameters.** Circulating LIF in serum was assessed by ELISA and divided according to (A) Stage of Differentiation (n=25), (B) Tumour stage (n=26), (C) Nodal Status (n=26) and (D) Body Mass Index (n=26). Mann-Whitney U test. Data are expressed as mean  $\pm$  SEM.



**Supplementary Figure 2: Relative expression of LIF in OAC pre-treatment biopsies.** Relative expression of LIF mRNA in patient tumour biopsies was divided according to clinical characteristics (A) Tumour Stage (n=20) (B) Nodal Status (n=20) (C) Presence of Metastasis (n=20) (D) Body Mass Index (n=20) (E) Clinical Stage (n=20) (F) Stage of Differentiation (n=20). Mann Whitney U test. Data expressed as mean  $\pm$  SEM.



**Supplementary Figure 3: Relative expression of LIFR in OAC pre-treatment biopsies.** Expression of LIF mRNA in patient tumour biopsies was divided according to clinical characteristics (A) Tumour Stage (n=15) (B) Nodal Status (n=15) (C) Presence of Metastasis (n=15) (D) Body Mass Index (n=15) (E) Clinical Stage (n=15) and (F) Stage of differentiation (n=15). Mann-Whitney U test. Data expressed as mean ± SEM.

**Supplementary Table 1: Patient characteristics of patient cohort for RT-PCR study**

|                           | <b>n=24</b>         |
|---------------------------|---------------------|
| Male                      | 20                  |
| Female                    | 4                   |
| Median Age at diagnosis   | 62.5 (43-75)        |
| Median BMI at diagnosis   | 27.34 (20.04-36.61) |
| Tumour Stage at diagnosis |                     |
| 2                         | 3                   |
| 3                         | 21                  |
| Nodal Status at diagnosis |                     |
| 0                         | 12                  |
| 1                         | 11                  |
| 2                         | 1                   |
| Treatment                 |                     |
| CROSS                     | 24                  |
| Tumour Regression Grade   |                     |
| 1                         | 4                   |
| 2                         | 8                   |
| 3                         | 6                   |
| 4                         | 6                   |

**Supplementary Table 2: Patient characteristics of patient cohort for serum study**

|                           | <b>n=26</b>  |
|---------------------------|--------------|
| Male                      | 23           |
| Female                    | 3            |
| Median Age at diagnosis   | 64.5 (58-80) |
| Median BMI at diagnosis   | 27 (23-36.8) |
| Tumour Stage at diagnosis |              |
| 1                         | 1            |
| 2                         | 2            |
| 3                         | 20           |
| 4                         | 1            |
| Not Specified             | 2            |
| Nodal Status at diagnosis |              |
| 0                         | 14           |
| 1                         | 8            |
| 2                         | 2            |
| No Specified              | 2            |
| Treatment                 |              |
| CROSS                     | 18           |
| MAGIC                     | 8            |
| Tumour Regression Grade   |              |
| 1                         | 5            |
| 2                         | 5            |
| 3                         | 9            |
| 4                         | 6            |
| 5                         | 1            |

**Supplementary Table 3: Patient characteristics of patient cohort for *ex-vivo* study**

|                           | <b>n=6</b>        |
|---------------------------|-------------------|
| Male                      | 5                 |
| Female                    | 1                 |
| Median Age                | 68.5 (61-83)      |
| Median BMI at diagnosis   | 30.15 (25.5-38.5) |
| Tumour Stage at diagnosis |                   |
| 2                         | 2                 |
| 3                         | 3                 |
| 4                         | 1                 |
| Nodal Status at diagnosis |                   |
| 0                         | 1                 |
| 1                         | 3                 |
| 2                         | 2                 |
| Treatment                 |                   |
| CROSS                     | 3                 |
| MAGIC                     | 1                 |
| Other Chemotherapy        | 2                 |
| Tumour Regression Grade   |                   |
| 3                         | 1                 |
| 4                         | 1                 |
| 5                         | 1                 |
| Not Specified             | 3                 |